

Supplementary Material

Predicted expenditure of prescription drugs for multiple sclerosis in the Italian market between 2023 and 2028: the results of Oracle Project

Damiano Paolicelli¹, Giovanna Borriello^{2,3}, Raffaella Clerici⁴, Elena Colombo⁵, Davide Croce⁶, Emanuele D'Amico⁷, Nicola De Rossi⁸, Alessia Di Sapio⁹, Giuseppe Fenu¹⁰, Davide Maimone¹¹, Girolama A. Marfia¹², Marcello Moccia^{13,14}, Paola Perini¹⁵, Maria G. Piscaglia¹⁶, Lorenzo Razzolini¹⁷, Massimo Riccaboni¹⁸, Elisabetta Signoriello¹⁹, Gianluca Agostoni²⁰, Alberto Farina²⁰, Margaret Mondino²⁰, Francesco Berruto²¹, Alessia Tettamanti²¹, Francesca Donnalaja^{21*}, Carla Tortorella²²

*Corresponding author

Francesca Donnalaja

IQVIA Solutions Italy S.r.l., Via Fabio Filzi, 29, 20124 Milano MI, Italy

Email: francesca.donnalaja@iqvia.com

¹ Department of Translational Biomedicines and Neurosciences, University of Bari Aldo Moro, Bari, Italy

² Multiple Sclerosis Center, San Pietro Fatebenefratelli Hospital, Rome, Italy

³ Department of Public Health, Federico II University, Naples, Italy

⁴ Operative Unit of Neurology, Valduce Hospital, Como, Italy

⁵ Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy

⁶ Centre for Health Economics, Social and Health Care Management, University Carlo Castanea - LIUC, Castellanza, Italy

⁷ Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

⁸ Multiple Sclerosis Center, ASST Spedali Civili di Brescia – P.O. Montichiari, Italy

⁹ Department of Neurology and CRESM (Regional Referral Multiple Sclerosis Centre), University Hospital San Luigi Gonzaga, Orbassano, Italy

¹⁰ Department of Neurology, Brotzu Hospital, Cagliari, Italy

¹¹ Centro Sclerosi Multipla, UOC Neurologia, Azienda Ospedaliera per l'Emergenza Cannizzaro, Catania, Italy

¹² Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy

¹³ Multiple Sclerosis Unit, Policlinico Federico II University Hospital of Naples, Naples, Italy ¹⁴ Department of Molecular Medicine and Medical Biotechnology, Federico II University of Naples, Italy

¹⁵ Department of Neurology, Multiple Sclerosis Center, University of Padua, Padua, Italy

¹⁶ Multiple Sclerosis Center, Santa Maria delle Croci Hospital, Ravenna, Italy

¹⁷ Department of Neurofarba, University of Florence, Florence, Italy


¹⁸ IMT School for Advanced Studies, Lucca, Italy

¹⁹ Second Division of Neurology, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy

²⁰ Sanofi Italy, Milan, Italy

²¹ IQVIA Solutions Italy S.r.l., Milan, Italy

²² Multiple Sclerosis Center, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy



Supplementary Figure 1. Selected analogues for evaluation of generics and biosimilars penetration on the left and analysis results on the right. Analogues were selected among products indicated in a chronic therapeutic area with the same reimbursement class (A or H) and distribution channel as multiple sclerosis (MS) products.

GX ANALOGUES					
ORIGINATOR	MOLECULE	INDICATION	FIRST GX LAUNCH	# GX	CLASS
Baraclude	entecavir	Hepatitis B	2017	6	A (PHT)
Tracleer	bosentan	Pulmonary hypertension	2017	9	A (PHT)
Reyataz	atazanavir	HIV	2019	5	H
Prezista	darunavir	HIV	2019	8	H

Economic Inputs (price cut)

- 89% discount applied to Gx vs originator pre-LoE ex-factory price (reached in 1 year)

- 70% discount applied to originator after Gx launch (reached in 2 years)[^]

BX ANALOGUES					
ORIGINATOR	MOLECULE	INDICATION	FIRST BX LAUNCH	# BX	CLASS
Enbrel	etanercept	Autoimmune diseases	2016	2	H RRL
Remicade	infliximab	Autoimmune diseases	2015	4	H RRL
Mabthera	rituximab	Oncohematology; Rheumatoid arthritis	2017	3	H OSP

Economic Inputs (price cut)


- 72% discount applied to Bx vs originator pre-LoE ex-factory price (reached in 3 years)

- 41% discount applied to originator after Bx launch (reached in 3 years)

Supplementary Figure 2. Selected analogs for evaluation of generics, biosimilars and originators tender discounts on the left and analysis results on the right. Analogs were selected among products indicated in a chronic therapeutic area with the same reimbursement class (A or H) and distribution channel as multiple sclerosis (MS) products.

RRL: Limited Repeated Prescription; OSP: Hospital use only.

**Total expenditure reduction between 2022 and 2028
(Baseline: €170 Millions)**



Supplementary Figure 3. Results of the sensitivity analysis conducted on the model. The variable considered was the total expenditure reduction between 2022 and 2028, equal to €170 mln. All parameters have been varied considering a +/- 20% variation of baseline values.

LoE: loss of exclusivity; NR-SPMS: non-relapsing secondary progressive multiple sclerosis; PMS: progressive multiple sclerosis; RMS: relapsing multiple sclerosis.